CO2020012588A2 - Composiciones de inhibidores de shp2, métodos para tratar el cáncer y metodos para identificar a un sujeto con mutaciones de shp2 - Google Patents
Composiciones de inhibidores de shp2, métodos para tratar el cáncer y metodos para identificar a un sujeto con mutaciones de shp2Info
- Publication number
- CO2020012588A2 CO2020012588A2 CONC2020/0012588A CO2020012588A CO2020012588A2 CO 2020012588 A2 CO2020012588 A2 CO 2020012588A2 CO 2020012588 A CO2020012588 A CO 2020012588A CO 2020012588 A2 CO2020012588 A2 CO 2020012588A2
- Authority
- CO
- Colombia
- Prior art keywords
- shp2
- methods
- mutations
- inhibitors
- identifying
- Prior art date
Links
- 230000035772 mutation Effects 0.000 title abstract 4
- 239000003112 inhibitor Substances 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 101710116241 Tyrosine-protein phosphatase non-receptor type 11 Proteins 0.000 abstract 4
- 102100033019 Tyrosine-protein phosphatase non-receptor type 11 Human genes 0.000 abstract 3
- 230000003281 allosteric effect Effects 0.000 abstract 2
- 229940125528 allosteric inhibitor Drugs 0.000 abstract 2
- 238000002405 diagnostic procedure Methods 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862655648P | 2018-04-10 | 2018-04-10 | |
| PCT/US2019/026543 WO2019199792A1 (en) | 2018-04-10 | 2019-04-09 | Shp2 inhibitor compositions, methods for treating cancer and methods for identifying a subject with shp2 mutations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2020012588A2 true CO2020012588A2 (es) | 2020-10-30 |
Family
ID=66248820
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2020/0012588A CO2020012588A2 (es) | 2018-04-10 | 2020-10-09 | Composiciones de inhibidores de shp2, métodos para tratar el cáncer y metodos para identificar a un sujeto con mutaciones de shp2 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20210154190A1 (https=) |
| EP (1) | EP3773590A1 (https=) |
| JP (1) | JP2021521155A (https=) |
| KR (1) | KR20200143417A (https=) |
| CN (1) | CN112203689A (https=) |
| AU (1) | AU2019251207A1 (https=) |
| BR (1) | BR112020020743A2 (https=) |
| CA (1) | CA3096535A1 (https=) |
| CO (1) | CO2020012588A2 (https=) |
| IL (1) | IL277783B2 (https=) |
| MX (1) | MX2020010719A (https=) |
| SG (1) | SG11202009793TA (https=) |
| TW (1) | TW201946627A (https=) |
| WO (1) | WO2019199792A1 (https=) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11466017B2 (en) | 2011-03-10 | 2022-10-11 | Board Of Regents, The University Of Texas System | Heterocyclic inhibitors of PTPN11 |
| JO3517B1 (ar) | 2014-01-17 | 2020-07-05 | Novartis Ag | ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2 |
| WO2017210134A1 (en) | 2016-05-31 | 2017-12-07 | Board Of Regents, University Of Texas System | Heterocyclic inhibitors of ptpn11 |
| WO2017216706A1 (en) | 2016-06-14 | 2017-12-21 | Novartis Ag | Compounds and compositions for inhibiting the activity of shp2 |
| EP4302834A3 (en) | 2016-07-12 | 2024-07-17 | Revolution Medicines, Inc. | 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors |
| WO2018057884A1 (en) | 2016-09-22 | 2018-03-29 | Relay Therapeutics, Inc. | Shp2 phosphatase inhibitors and methods of use thereof |
| TW202500565A (zh) | 2016-10-24 | 2025-01-01 | 美商傳達治療有限公司 | Shp2磷酸酶抑制劑及其使用方法 |
| JP7240319B2 (ja) | 2017-01-23 | 2023-03-15 | レヴォリューション・メディスンズ，インコーポレイテッド | アロステリックｓｈｐ２阻害剤としての二環式化合物 |
| KR20190110588A (ko) | 2017-01-23 | 2019-09-30 | 레볼루션 메디슨즈, 인크. | 알로스테릭 shp2 억제제로서의 피리딘 화합물 |
| EP3630770B1 (en) | 2017-05-26 | 2024-08-28 | Relay Therapeutics, Inc. | Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors |
| CA3074690A1 (en) | 2017-09-07 | 2019-03-14 | Revolution Medicines, Inc. | Shp2 inhibitor compositions and methods for treating cancer |
| EP3687997A1 (en) | 2017-09-29 | 2020-08-05 | Relay Therapeutics, Inc. | Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors |
| TW201930292A (zh) | 2017-10-12 | 2019-08-01 | 美商銳新醫藥公司 | 作為變構ｓｈｐ２抑制劑的吡啶、吡嗪和三嗪化合物 |
| JP7361693B2 (ja) | 2017-12-15 | 2023-10-16 | レヴォリューション・メディスンズ，インコーポレイテッド | アロステリックｓｈｐ２阻害剤としての多環式化合物 |
| AU2019240299B2 (en) | 2018-03-21 | 2023-06-22 | D.E. Shaw Research, Llc | SHP2 phosphatase inhibitors and methods of use thereof |
| US12138263B2 (en) | 2018-03-21 | 2024-11-12 | Relay Therapeutics, Inc. | Pyrazolo[3,4-b]pyrazine SHP2 phosphatase inhibitors and methods of use thereof |
| MX2020011528A (es) | 2018-05-02 | 2021-02-09 | Navire Pharma Inc | Inhibidores heterociclicos sustituidos de ptpn11. |
| CN112601750B (zh) | 2018-08-10 | 2023-10-31 | 纳维尔制药有限公司 | Ptpn11（shp2）抑制剂 |
| EP3860717A1 (en) | 2018-10-03 | 2021-08-11 | Gilead Sciences, Inc. | Imidozopyrimidine derivatives |
| CN117143079A (zh) | 2018-11-06 | 2023-12-01 | 上海奕拓医药科技有限责任公司 | 一种螺芳环化合物及其应用 |
| CN111647000B (zh) | 2019-03-04 | 2021-10-12 | 勤浩医药（苏州）有限公司 | 吡嗪类衍生物及其在抑制shp2中的应用 |
| CN115141205A (zh) | 2019-06-07 | 2022-10-04 | 锐新医药公司 | Shp2抑制剂的固体形式 |
| MX2022003454A (es) | 2019-09-24 | 2022-04-19 | Relay Therapeutics Inc | Inhibidores de fosfatasa shp2 y metodos para su fabricacion y uso. |
| CN112724145A (zh) * | 2019-10-14 | 2021-04-30 | 杭州雷索药业有限公司 | 用于抑制shp2活性的吡嗪衍生物 |
| CA3156359A1 (en) | 2019-11-08 | 2021-05-14 | Adrian Liam Gill | Bicyclic heteroaryl compounds and uses thereof |
| EP4069301A1 (en) * | 2019-12-04 | 2022-10-12 | Bayer Aktiengesellschaft | Inhibitors of shp2 |
| CN111265529B (zh) * | 2020-02-22 | 2021-07-23 | 南京大学 | 蛋白酪氨酸磷酸酶shp2抑制剂在制备治疗银屑病药物中的应用 |
| EP4110338A1 (en) | 2020-02-28 | 2023-01-04 | Novartis AG | A triple pharmaceutical combination comprising dabrafenib, an erk inhibitor and a shp2 inhibitor |
| JP2024516997A (ja) | 2021-05-05 | 2024-04-18 | フヤバイオ インターナショナル，エルエルシー | Ｓｈｐ２阻害剤単独療法およびその使用 |
| IL308222A (en) | 2021-05-05 | 2024-01-01 | Huyabio Int Llc | Combination therapies that include SHP2 inhibitors and PD-1 inhibitors |
| AU2022274936B2 (en) * | 2021-05-13 | 2025-08-21 | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Heterocyclic compound for inhibiting shp2 activity, preparation method therefor and use thereof |
| WO2022259157A1 (en) | 2021-06-09 | 2022-12-15 | Novartis Ag | A triple pharmaceutical combination comprising dabrafenib, trametinib and a shp2 inhibitor |
| TW202317100A (zh) | 2021-06-23 | 2023-05-01 | 瑞士商諾華公司 | 包含ｋｒａｓ ｇ１２ｃ抑制劑的藥物組合及其用於治療癌症之用途 |
| KR20240055778A (ko) | 2021-09-01 | 2024-04-29 | 노파르티스 아게 | Tead 억제제를 포함하는 제약 조합물 및 암의 치료를 위한 이의 용도 |
| CN116063307B (zh) | 2021-10-29 | 2025-08-19 | 中国药科大学 | Shp2与cdk4/6双靶点抑制化合物合成及其制备方法与应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5262564A (en) | 1992-10-30 | 1993-11-16 | Octamer, Inc. | Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents |
| WO2003029422A2 (en) * | 2001-10-01 | 2003-04-10 | Mount Sinai School Of Medicine | Noonan syndrome gene |
| EP1948827B1 (en) * | 2005-10-21 | 2016-03-23 | The Regents of The University of California | C-kit oncogene mutations in melanoma |
| NZ713361A (en) | 2009-08-17 | 2017-06-30 | Memorial Sloan Kettering Cancer Center | Heat shock protein binding compounds, compositions, and methods for making and using same |
| US8673913B2 (en) * | 2009-11-13 | 2014-03-18 | Case Western Reserve University | SHP-2 phosphatase inhibitor |
| EP2826586A1 (en) | 2013-07-18 | 2015-01-21 | Siemens Aktiengesellschaft | A method and a system for machining an object |
| WO2015107494A1 (en) | 2014-01-17 | 2015-07-23 | Novartis Ag | 1 -(triazin-3-yi_/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions thereof for inhibiting the activity of shp2 |
| ES2699351T3 (es) | 2014-01-17 | 2019-02-08 | Novartis Ag | Derivados de 1-piridazin/triazin-3-il-piper(-azina)/idina/pirolidina y composiciones de las mismas para inhibir la actividad de SHP2 |
| JO3517B1 (ar) * | 2014-01-17 | 2020-07-05 | Novartis Ag | ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2 |
| US10287266B2 (en) | 2015-06-19 | 2019-05-14 | Novartis Ag | Compounds and compositions for inhibiting the activity of SHP2 |
| WO2016203405A1 (en) | 2015-06-19 | 2016-12-22 | Novartis Ag | Compounds and compositions for inhibiting the activity of shp2 |
| EP3310779B1 (en) | 2015-06-19 | 2019-05-08 | Novartis AG | Compounds and compositions for inhibiting the activity of shp2 |
| WO2017079723A1 (en) | 2015-11-07 | 2017-05-11 | Board Of Regents, The University Of Texas System | Targeting proteins for degradation |
| WO2017156397A1 (en) | 2016-03-11 | 2017-09-14 | Board Of Regents, The University Of Texas Sysytem | Heterocyclic inhibitors of ptpn11 |
| MX388576B (es) | 2016-06-07 | 2025-03-20 | Jacobio Pharmaceuticals Co Ltd | Derivados heterociclicos novedosos utiles como inhibidores de shp2. |
| EP4302834A3 (en) | 2016-07-12 | 2024-07-17 | Revolution Medicines, Inc. | 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors |
-
2019
- 2019-04-09 MX MX2020010719A patent/MX2020010719A/es unknown
- 2019-04-09 WO PCT/US2019/026543 patent/WO2019199792A1/en not_active Ceased
- 2019-04-09 TW TW108112247A patent/TW201946627A/zh unknown
- 2019-04-09 IL IL277783A patent/IL277783B2/en unknown
- 2019-04-09 SG SG11202009793TA patent/SG11202009793TA/en unknown
- 2019-04-09 CA CA3096535A patent/CA3096535A1/en active Pending
- 2019-04-09 BR BR112020020743-8A patent/BR112020020743A2/pt not_active IP Right Cessation
- 2019-04-09 KR KR1020207032251A patent/KR20200143417A/ko not_active Ceased
- 2019-04-09 CN CN201980037528.7A patent/CN112203689A/zh active Pending
- 2019-04-09 JP JP2020555352A patent/JP2021521155A/ja active Pending
- 2019-04-09 EP EP19719088.7A patent/EP3773590A1/en not_active Withdrawn
- 2019-04-09 AU AU2019251207A patent/AU2019251207A1/en not_active Abandoned
-
2020
- 2020-10-06 US US17/064,317 patent/US20210154190A1/en not_active Abandoned
- 2020-10-09 CO CONC2020/0012588A patent/CO2020012588A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3096535A1 (en) | 2019-10-17 |
| SG11202009793TA (en) | 2020-10-29 |
| IL277783B2 (en) | 2024-07-01 |
| IL277783A (en) | 2020-11-30 |
| IL277783B1 (en) | 2024-03-01 |
| MX2020010719A (es) | 2020-11-06 |
| KR20200143417A (ko) | 2020-12-23 |
| AU2019251207A1 (en) | 2020-11-19 |
| JP2021521155A (ja) | 2021-08-26 |
| EP3773590A1 (en) | 2021-02-17 |
| US20210154190A1 (en) | 2021-05-27 |
| CN112203689A (zh) | 2021-01-08 |
| TW201946627A (zh) | 2019-12-16 |
| WO2019199792A1 (en) | 2019-10-17 |
| BR112020020743A2 (pt) | 2021-02-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2020012588A2 (es) | Composiciones de inhibidores de shp2, métodos para tratar el cáncer y metodos para identificar a un sujeto con mutaciones de shp2 | |
| CO2020002588A2 (es) | Composiciones que comprenden un inhibidor de shp2 y metodos para tratar el cáncer | |
| CY1124307T1 (el) | Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρησεις αυτων | |
| NZ763161A (en) | Inhibition of hsd17b13 in the treatment of liver disease in patients expressing the pnpla3 i148m variation | |
| ECSP19043725A (es) | Composiciones de aminoácidos y métodos para el tratamiento de enfermedades y trastornos musculares | |
| MX2019003934A (es) | Métodos terapéuticos y de diagnóstico para el cáncer. | |
| MX2018010361A (es) | Métodos terapéuticos y de diagnóstico para el cáncer. | |
| PH12020551683A1 (en) | Biomarkers for graft-versus-host disease | |
| AR098155A1 (es) | Métodos para diagnosticar y tratar trastornos eosinofílicos | |
| MX352789B (es) | Anticuerpo anti-il-13 para usarse en tratar un asma o un trastorno respiratorio. | |
| NZ712184A (en) | Combination therapy comprising a b-raf inhibitor and a second inhibitor | |
| MX2017014736A (es) | Metodos terapeuticos y diagnosticos para cancer. | |
| CO2019009586A2 (es) | Anticuerpos anti-gitr y métodos de uso de los mismos | |
| EA201890891A1 (ru) | Биомаркеры, связанные с заболеваниями, опосредованными интерлейкином-33 (ил-33), и их применение | |
| MX2017011486A (es) | Métodos de detección y cuantificación de il-13 y sus usos en el diagnóstico y tratamiento de enfermedades asociadas a th2. | |
| EA201890957A1 (ru) | Комбинированная терапия для лечения злокачественных опухолей | |
| CL2020000382A1 (es) | Composiciones de aminoácidos para el tratamiento de enfermedad hepática. | |
| BR112014011925A2 (pt) | mutações no receptor notch humano e seu uso | |
| MX2014014097A (es) | Biomarcadores para determinar la respuesta eficaz de tratamientos en pacientes de carcinoma hepatocelular (chc). | |
| BR112018000254A2 (pt) | inibidores de pde9 com cadeia principal de imidazotriazinona e cadeia principal de imidazopirazinona para o tratamento de doenças periféricas | |
| AU2016304856A8 (en) | Mechanism of resistance to BET bromodomain inhibitors | |
| MX336498B (es) | Identificacion, evaluacion y terapia de canceres con resistencia innata o adquirida a inhibidores alk. | |
| EA201790352A1 (ru) | Терапевтическое лечение на основе анаморелина | |
| EA201792641A1 (ru) | Ингибитор оси igfbp3/tmem219 и диабет | |
| BR112012026224A2 (pt) | métodos para tratar mal de alzheimer e para avaliar a eficácia de uma terapia |